Eszopiclone
Back to searchMolecule Structure
Scientific Name
Eszopiclone
Description of the Drug
Eszopiclone is a sedative-hypnotic used in the treatment of insomnia, improving both the latency phase and the maintenance phase of sleep.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-02-07 from
http://www.drugbank.ca/drugs/DB00402
http://www.drugbank.ca/drugs/DB00402
Brand Name(s)
Eszopiclone, Lunesta
Company Owner(s)
Nostrum Laboratories Inc, Mylan Pharmaceuticals Inc, Hikma Pharmaceuticals Usa Inc, Orchid Healthcare, Macleods Pharmaceuticals Ltd, Glenmark Generics Ltd, Sunovion Pharmaceuticals Inc, Dr Reddys Laboratories Ltd, Wockhardt Ltd, Lupin Ltd
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| GABA-A receptor; anion channel | PROTEIN COMPLEX GROUP | POSITIVE ALLOSTERIC MODULATOR | CHEMBL2093872 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL28657 | |
| PharmGKB | PA162630444 | |
| Human Metabolome Database | HMDB0014546 | |
| DrugBank | DB00402 | |
| PubChem: Thomson Pharma | 14927588 | |
| PubChem | 969472 | |
| Mcule | MCULE-5099990703 | MCULE-3167182309 |
| Nikkaji | J573.434G | |
| EPA CompTox Dashboard | DTXSID8046086 | |
| DrugCentral | 1068 | |
| ChemicalBook | CB1468825 | |
| Guide to Pharmacology | 7429 | |
| GSRS | f2d65111-ecbc-45fb-b51e-6753757e6511 | |
| rxnorm | LUNESTA | ESZOPICLONE |
| PubChem: Drugs of the Future | 12015386 | |
| ChEBI | 53760 | |
| NIH Clinical Collection | SAM002548982 | |
| ZINC | ZINC000019632834 |
